Evidence map›Paper›PMID 20010625›Full record

Trial reportLeukemia2010

Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000.

A Möricke, M Zimmermann, A Reiter, G Henze, A Schrauder, H Gadner, W D Ludwig, J Ritter, J Harbott, G Mann and 11 more

2 registry-linked trialsAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Leukemia, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 188 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
188citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01117441 phase3completednot on this map

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia

TypeinterventionalSponsorUniversity Hospital Schleswig-HolsteinRan2010 to 2021Enrolled6,136ConditionsLeukemiaArmsPEG-L-asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone
NCT03605589 phase1withdrawnnot on this mapstarted 2018, after this paper: background citation

A Pilot Study of Blinatumomab in Combination With a PD1 Inhibitor, Pembrolizumab, in Pediatric and Young Adult Patients With Relapsed/Refractory CD19 Positive B-cell Acute Leukemia or Lymphoma

TypeinterventionalSponsorChildren's Hospital Medical Center, CincinnatiRan2018 to 2022Enrolled0ConditionsLeukemia, B-cell, Lymphoma, B-CellArmsBlinatumomab, Pembrolizumab
3 · Its place in the literature

Who cites it

188 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016
    Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

128 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

A MörickeDepartment of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
M Zimmermann
A Reiter
G Henze
A Schrauder
H Gadner
W D Ludwig
J Ritter
J Harbott
G Mann
T Klingebiel
F Zintl
C Niemeyer
B Kremens
F Niggli
D Niethammer
K Welte
M Stanulla
E Odenwald
H Riehm
M Schrappe

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Between 1981 and 2000, 6609 children (<18 years of age) were treated in five consecutive trials of the Berlin-Frankfurt-Münster (BFM) study group for childhood acute lymphoblastic leukemia (ALL). Patients were treated in up to 82 centers in Germany, Austria and Switzerland. Probability of 10-year event-free survival (EFS) (survival) improved from 65% (77%) in study ALL-BFM 81 to 78% (85%) in ALL-BFM 95. In parallel to relapse reduction, major efforts focused on reducing acute and late toxicity through advanced risk adaptation of treatment. The major findings derived from these ALL-BFM trials were as follows: (1) preventive cranial radiotherapy could be safely reduced to 12 Gy in T-ALL and high-risk (HR) ALL patients, and eliminated in non- HR non-T-ALL patients, if it was replaced by high-dose and intrathecal (IT) MTX; (2) omission of delayed re-intensification severely impaired outcome of low-risk patients; (3) 6-month-less maintenance therapy caused an increase in systemic relapses; (4) slow response to an initial 7-day prednisone window was identified as adverse prognostic factor; (5) condensed induction therapy resulted in significant improvement of outcome; (6) the daunorubicin dose in induction could be safely reduced in low-risk patients and (7) intensification of consolidation/re-intensification treatment led to considerable improvement of outcome in HR patients.

Indexed as

Cranial IrradiationStem Cell TransplantationAdolescentAntineoplastic Combined Chemotherapy ProtocolsChildChild, PreschoolCombined Modality TherapyFemaleFollow-Up StudiesHumansImmunophenotypingInfantMaleNeoplasm Recurrence, LocalPrecursor Cell Lymphoblastic Leukemia-LymphomaPrognosis

Identifiers

PMID20010625

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.